Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS. In this episode, we discuss: Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs acr...
All content for Business Trip is the property of Greg Kubin & Matias Serebrinsky and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS. In this episode, we discuss: Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs acr...
Frontier investable areas in brain health with PsyMed Ventures
Business Trip
49 minutes
9 months ago
Frontier investable areas in brain health with PsyMed Ventures
Greg and Matias sit down with Brooks Leitner, the newest partner at PsyMed Ventures, to explore the future of brain and mental health investing. Brooks, an MD/PhD with deep experience from Yale and the NIH, shares his insights on how a human-first approach is reshaping neuroscience innovation and venture investing. In this episode, we discuss: Broadening the Thesis: Evolving from a psychedelics-only focus to a comprehensive neuro investment strategy.Human-First Research: Shifting from a...
Business Trip
Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS. In this episode, we discuss: Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs acr...
